BioMarin Pharmaceutical Inc. (BMRN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Rafael, CA, United States. The current CEO is Alexander Hardy.
BMRN has IPO date of 1999-07-26, 3,040 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $10.67B.
BioMarin Pharmaceutical Inc. is a biopharmaceutical company that develops and commercializes therapies for rare and life-threatening genetic and metabolic diseases. The company's approved commercial products include Vimizim and Naglazyme for mucopolysaccharidosis disorders, Kuvan and Palynziq for phenylketonuria, Brineura for Batten disease, Voxzogo for achondroplasia, and Aldurazyme for lysosomal storage disease. BioMarin's pipeline includes late-stage gene therapy candidates such as valoctocogene roxaparvovec for hemophilia A and BMN 307 for phenylketonuria, along with BMN 255 in development for primary hyperoxaluria. The company distributes its products globally through specialty pharmacies, hospitals, and pharmaceutical wholesalers across the United States, Europe, Latin America, and international markets, while maintaining strategic partnerships with leading biotechnology firms.
